Medication Options for Refractory Insomnia in Acute Psychiatric Setting

Direct Recommendation

The American Academy of Sleep Medicine recommends adding a benzodiazepine receptor agonist, such as zolpidem 10mg or eszopiclone 2-3mg at bedtime, for patients with refractory insomnia in an acute psychiatric setting, as trazodone 100mg has already failed and guidelines explicitly recommend against its use for insomnia 1, 2

The American Academy of Sleep Medicine recommends zolpidem 10mg at bedtime for both sleep onset and maintenance insomnia, showing a mean improvement of 29 minutes in total sleep time and 25 minutes reduction in wake after sleep onset compared to placebo, with a moderate strength of evidence 1, 4, 5
The American Academy of Sleep Medicine recommends eszopiclone 2-3mg at bedtime for sleep maintenance insomnia, showing mean improvements of 28-57 minutes in total sleep time and moderate-to-large improvements in sleep quality, with a moderate strength of evidence 1, 4, 5
Zaleplon 10mg is specifically useful if the primary issue is sleep onset difficulty, with minimal next-day effects due to its very short half-life, and is recommended by the American Academy of Sleep Medicine for sleep onset insomnia 1, 5
Temazepam 15mg is effective for both sleep initiation and maintenance, showing a mean improvement of 99 minutes in total sleep time, though it carries slightly higher risk of residual morning sedation, and is recommended by the American Academy of Sleep Medicine for both sleep onset and maintenance insomnia 1, 4

Ramelteon 8mg at bedtime is particularly appropriate if there are concerns about controlled substances or substance use history, as it carries no dependence risk and works through melatonin receptors in the suprachiasmatic nucleus to regulate sleep/wake rhythm, and is recommended by the American Academy of Sleep Medicine for sleep onset insomnia 1, 5

Doxepin 3-6mg at bedtime is specifically recommended for sleep maintenance insomnia, showing mean improvements of 26-32 minutes in total sleep time and 22-23 minutes reduction in wake after sleep onset, with a low strength of evidence 1, 4

The American Academy of Sleep Medicine recommends against using trazodone for either sleep onset or sleep maintenance insomnia, with a WEAK recommendation against its use because harms potentially outweigh benefits, and evidence shows no improvement in subjective sleep quality even at 50mg, and higher doses only increase adverse effects including daytime drowsiness, dizziness, and psychomotor impairment 1, 2, 3
The American Academy of Sleep Medicine recommends against using diphenhydramine, melatonin, valerian, or L-tryptophan for insomnia treatment due to lack of efficacy, with a moderate strength of evidence 1, 4
The American Academy of Sleep Medicine recommends against using alprazolam for insomnia treatment, as it is not among the benzodiazepines specifically recommended for insomnia and carries risk of rebound anxiety, with a low strength of evidence 5

Caution with additive sedation is required when adding a BzRA to a patient already on olanzapine 15mg and trazodone 100mg, and monitoring for excessive sedation is necessary, though this combination is commonly used in acute psychiatric settings, with a moderate strength of evidence 2
Benzodiazepine risks, including dependence, tolerance, withdrawal symptoms, residual sedation, memory impairment, falls, and undesired sleep behaviors, should be considered when prescribing BzRAs, with a high strength of evidence 5

Start zolpidem 10mg at bedtime for both sleep onset and maintenance issues, with a moderate strength of evidence, and ensure adequate sleep time (7-8 hours) available, and administer on empty stomach to maximize efficacy 1, 5
If inadequate response after 1-2 weeks, switch to eszopiclone 2-3mg for better sleep maintenance throughout the night, or zaleplon 10mg if only sleep onset is the issue, with a moderate strength of evidence 1, 5
If BzRAs are contraindicated or fail, consider ramelteon 8mg for sleep onset issues, or doxepin 3-6mg for sleep maintenance issues, with a low strength of evidence 1, 4, 5

Acute vs. chronic use: In the acute psychiatric setting, short-term use of BzRAs is appropriate and guideline-supported, but plan for eventual transition to non-pharmacologic approaches once acute symptoms stabilize, with a moderate strength of evidence 1, 2
Lowest effective dose, shortest duration: All hypnotics should be used at the lowest effective dose and for the shortest possible duration, with regular reassessment of ongoing need, with a high strength of evidence 2, 5